An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer - Scorecard - MDSpire
Advertisement
An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer
Clinical Scorecard: An Integrative Analysis of Plasma Transcriptomic and Proteomic Biomarkers Predicting Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer
At a Glance
Category
Detail
Condition
Key Mechanisms
Differentially expressed genes (DEGs) and proteins (DEPs) associated with treatment response to total neoadjuvant therapy (TNT) should be directly sourced.
Target Population
Care Setting
Key Highlights
Remove claims about correlation with higher pCR rates unless directly supported.
Guideline-Based Recommendations
Diagnosis
Management
E
n
s
u
r
e
m
a
n
a
g
e
m
e
n
t
s
t
r
a
t
e
g
i
e
s
a
r
e
d
i
r
e
c
t
l
y
c
i
t
e
d
f
r
o
m
t
h
e
s
t
u
d
y
.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients aged 18 years or older with stage II–III rectal cancer
Involves radiotherapy and CAPOX regimen chemotherapy prior to curative resection
Clinical Best Practices
Remove any interpretations or implications not directly supported by the source.
